Captrust Financial Advisors Aim Immuno Tech Inc. Transaction History
Captrust Financial Advisors
- $30.9 Billion
- Q2 2024
A detailed history of Captrust Financial Advisors transactions in Aim Immuno Tech Inc. stock. As of the latest transaction made, Captrust Financial Advisors holds 20,000 shares of AIM stock, worth $4,600. This represents 0.0% of its overall portfolio holdings.
Number of Shares
20,000
Previous 20,000
-0.0%
Holding current value
$4,600
Previous $9,000
22.22%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding AIM
# of Institutions
40Shares Held
8.53MCall Options Held
0Put Options Held
0-
Armistice Capital, LLC New York, NY4.08MShares$937,9400.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.99MShares$457,4010.0% of portfolio
-
Black Rock Inc. New York, NY698KShares$160,6010.0% of portfolio
-
Geode Capital Management, LLC Boston, MA464KShares$106,7230.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny229KShares$52,6250.0% of portfolio
About AIM ImmunoTech Inc.
- Ticker AIM
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,049,300
- Market Cap $11.1M
- Description
- AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's products include Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome...